-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

Sponsor: MorphoSys and Protagonist Therapeutics Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Drug development, Education, Treatment Considerations
Friday, December 6, 2024: 3:00 PM-6:00 PM
Ballroom 20CD (San Diego Convention Center)
Chair:
Rami S. Komrokji, MD, ARRAY(0xd6ba074)
Disclosures:
Komrokji: Novartis: Membership on an entity's Board of Directors or advisory committees; Taiho: Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servio: Honoraria; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; Servio: Membership on an entity's Board of Directors or advisory committees.
Speakers:
Gabriela S. Hobbs, MD, Massachusetts General Hospital and Barbara Mora, MD, ARRAY(0xeb500b8)
Disclosures:
Hobbs: Sobi: Honoraria; Novartis: Honoraria; GSK: Honoraria; Cogent: Honoraria; Pfizer: Honoraria; BMS: Honoraria; Abbvie: Honoraria; Incyte: Honoraria, Research Funding; Regeneron: Other: spouse employment; Pharmaessentia: Honoraria. Mora: Novartis: Speakers Bureau.

Medical Crossfire® is one of PER’s signature educational formats and is a nationally-recognized medical education modality dedicated to improving medical practices and patient care through debate, discussion, and authoritative peer exchange on critical clinical issues. The design of the Medical Crossfire® is based on the understanding that exposure to differing – and sometimes provocative – opinions, insights, and philosophies fuels improved learning and knowledge among healthcare professionals. This Medical Crossfire® formatted satellite program will include a chair and panel of four faculty experts in MPNs, featuring a series of brief didactic presentations, followed by discussion between faculty on key questions and common cases in the field.

To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.